In-vivo Bioequivalence Test of Escitalopram tablet with brand drug Cipralex Made by Loundbeck A/S Denmark.

Pharmacokinetic assessments of Escitalopram tablet with brand drugs (Cipralex 20mg Loundbeck A/S Denmark).

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200105046010N14

Enrollment

Registered

2020-11-02

Start date

2020-12-24

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

In this study, the disease is not examined. Subject bioequivalence test and reference tablets Escitalopram studied..

Interventions

Intervention 1: Intervention group: Single dose Escitalopram tablet 20mg Abidi Pharmaceutical Company. Intervention 2: Control group:Single dose of Cipralex tablet with brand drugs 20mg Loundbeck A/

Eligibility

Sex/Gender

Male

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: General health (liver, heart, kidney) Body mass index(18-28) Informed consent Age(18-60)

Exclusion criteria

Exclusion criteria: Smoking Pregnancy Alcohol & Drug addiction

Design outcomes

Primary

Measure	Time frame
Determination of blood drug concentration. Timepoint: Sampling times in this study will be 0, 1, 2, 2:30, 3, 3:20, 3:40, 4, 4:20, 4: 40, 5, 6, 8, 10, 12, 24, 48, 72 hours. Method of measurement: Liquid Chromatography with tandem mass spectroscopy detector.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJavad Shokri

Tabriz University of Medical Sciences

Shokri.j@gmail.com+98 41 3334 8489

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026